Literature DB >> 6978134

A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus.

M I Hamburger, T J Lawley, R P Kimberly, P H Plotz, M M Frank.   

Abstract

A serial study of reticuloendothelial system splenic Fc receptor function was undertaken in 13 patients with systemic lupus erythematosus (SLE). Fc receptor function was assessed by measuring the clearance half times of IgG-sensitized 51Cr-labeled autologous erythrocytes from the circulation. Prolonged clearance half times were initially detected in all patients, and the magnitude of the clearance defect was significantly correlated with disease activity (P less than 0.01, Spearman rank correlation) and immune complex levels (P less than 0.01). Clinical course and changes in receptor functional activity over time were found to be significantly correlated. Clearance half-times tended to return to normal in all 11 patients who clinically improved. The clearance half-time remained unchanged in 1 patient whose disease activity was stable, and it worsened in 1 patient whose illness flared. Levels of immune complexes also changed concordantly with clearance half-times and disease activity. These studies underscore the interrelationship between the presence of circulating immune complexes, defects in Fc receptor function that might lead to prolonged circulation of these complexes, and disease activity in SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978134     DOI: 10.1002/art.1780250108

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity.

Authors:  Robert P Kimberly; Jianming Wu; Andrew W Gibson; Kaihong Su; Hongwe Qin; Xiaoli Li; Jeffrey C Edberg
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  B cells in glomerulonephritis: focus on lupus nephritis.

Authors:  Menna R Clatworthy; Kenneth G C Smith
Journal:  Semin Immunopathol       Date:  2007-10-18       Impact factor: 9.623

Review 3.  Fcgamma receptors: structure, function and role as genetic risk factors in SLE.

Authors:  X Li; T S Ptacek; E E Brown; J C Edberg
Journal:  Genes Immun       Date:  2009-05-07       Impact factor: 2.676

4.  Immune complex processing in C1q-deficient mice.

Authors:  J T Nash; P R Taylor; M Botto; P J Norsworthy; K A Davies; M J Walport
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 5.  The aetiology and pathogenesis of major systemic vasculitides.

Authors:  C O Savage; Y C Ng
Journal:  Postgrad Med J       Date:  1986-07       Impact factor: 2.401

6.  Reticuloendothelial Fc receptor function in SLE patients. II. Associations with humoral immune response parameters in vivo and in vitro.

Authors:  F J van der Woude; C G Kallenberg; P C Limburg; H Beekhuis; W Ouwehand; M van der Giessen; P J Hoedemaeker; G K van der Hem; T H The
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

7.  The splenic extraction ratio of antibody-coated erythrocytes and its response to plasma exchange and pulse methylprednisolone.

Authors:  M J Walport; A M Peters; K B Elkon; C D Pusey; J P Lavender; G R Hughes
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

8.  The stimulation of IL-2 production by anti-rheumatic drugs.

Authors:  J A Oben; G R Wallace; B M Chain; J C Foreman
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

9.  Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).

Authors:  N P Hurst; G Nuki; T Wallington
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

10.  Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees.

Authors:  S Lobatto; M R Daha; A A Voetman; J H Evers-Schouten; A A Van Es; E K Pauwels; L A Van Es
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.